


**AMENDMENTS TO THE SPECIFICATION**

**Please replace the paragraph at page 4, lines 9-18 with the following amended paragraph:**

Preferably the radical initiator is of the general formula V



where:

$\text{Y}^1$  is selected from the group consisting of Cl, Br, I,  $\text{OR}^{10}$ ,  $\text{SR}^{14}$ ,  $\text{SeR}^{14}$ ,  $\text{OP}(=\text{O})\text{R}^{14}$ ,  $\text{OP}(=\text{O})(\text{OR}^{14})_2$ ,  $\text{O}-\text{N}(\text{R}^{14})_2$  and  $\text{S}-\text{C}(=\text{S})\text{N}(\text{R}^{14})_2$ , where  $\text{R}^{10}$  is alkyl of from 1 to 20 carbon atoms in which each of the hydrogen atoms may be independently replaced by halide,  $\text{R}^{14}$  is aryl or a straight or branched  $\text{C}_1$ - $\text{C}_{20}$  alkyl group, and where an  $\text{N}(\text{R}^{14})_2$  group is present, the two  $\text{R}^{14}$  groups may be joined to form a 5- or 6-membered heterocyclic ring;

**Please replace the paragraph at page 4, lines 19-26 with the following amended paragraph:**

$\text{R}^{11}$  and  $\text{R}^{12}$  are each independently selected from the group consisting of H, halogen,  $\text{C}_1$ - $\text{C}_{20}$  alkyl,  $\text{C}_3$ - $\text{C}_8$  cycloalkyl,  $\text{C}(=\text{O})\text{R}^{15}$ ,  $\text{C}(=\text{O})\text{NR}^{16}\text{R}^{17}$ ,  $\text{COCl}$ ,  $\text{OH}$ ,  $\text{CN}$ ,  $\text{C}_2$ - $\text{C}_{20}$  alkenyl, oxiranyl, glycidyl, aryl, heterocyclyl, aralkyl and aralkenyl, in any of which the alkyl, alkenyl or aryl, heterocyclyl or cycloalkyl groups there may be from 1 to 3 substituents selected from the group consisting of hydrogen, hydroxy  $\text{C}_1$ - $\text{C}_4$  alkoxy, acyloxy, aryl, heterocyclyl,  $\text{C}(=\text{O})\text{R}^{15}$ ,  $\text{C}(=\text{O})\text{NR}^{16}\text{R}^{17}$ ,  $-\text{CR}^{12}\text{R}^{13}\text{Y}-\text{CR}^{12}\text{R}^{13}\text{Y}^1$ ,  $\text{CR}^{11}\text{R}^{12}\text{Y}^1\text{CR}^{14}\text{R}^{12}\text{Y}$ , oxiranyl and glycidyl;

**Please replace the paragraph at page 5, lines 8-16 with the following amended paragraph:**

$R^{13}$  is selected from the group consisting of biologically active group-substituted alkyl, cycloalkyl,  $-\text{COR}^{15}$ ,  $-\text{CONR}^{16}\text{R}^{17}$ , alkenyl, aryl, heterocyclyl, aralkyl and aralkenyl groups, in any of which the alkyl, alkenyl, aryl, heterocyclyl or cycloalkyl groups may have from 1 to 3 substituents selected from the group consisting of hydrogen, hydroxy,  $\text{C}_1$ - $\text{C}_4$  alkoxy, acyloxy, aryl, heterocyclyl,  $\text{C}(=\text{O})\text{R}^{15}$ ,  $\text{C}(=\text{O})\text{NR}^{16}\text{R}^{17}$ ,  $-\text{CR}^{12}\text{R}^{13}\text{Y}^1$ ,  $-\text{CR}^{12}\text{R}^{13}\text{Y}$ ,  $\text{CR}^{11}\text{R}^{12}\text{Y}$ ,  $\text{CR}^{11}\text{R}^{12}\text{Y}^1$ , oxiranyl and glycidyl where  $\text{R}^{15}$ ,  $\text{R}^{16}$  and  $\text{R}^{17}$  are groups as defined above for  $\text{R}^{11}$  and  $\text{R}^{12}$  with the biologically active group substituted on an alkyl, cycloalkyl, alkenyl, aryl or heterocyclyl group.

**Please replace the paragraph at page 5, lines 23-25 with the following amended paragraph:**

Since any of  $\text{R}^{11}$ ,  $\text{R}^{12}$  and  $\text{R}^{13}$  may comprise a substituent  $\text{CR}^{12}\text{R}^{13}$  or  $-\text{CR}^{11}\text{R}^{12}\text{Y}$   $\text{CR}^{11}\text{R}^{12}\text{Y}^1$ , the initiator may be di-, oligo- or poly- functional. Preferably it is a mono-functional initiator.